trending Market Intelligence /marketintelligence/en/news-insights/trending/jK_ereZ9P75EzRBqgS9c3g2 content esgSubNav
In This List

US FDA grants fast track designation to Radius Health's breast cancer drug

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


US FDA grants fast track designation to Radius Health's breast cancer drug

The U.S. Food and Drug Administration granted fast-track designation to Radius Health Inc.'s breast cancer drug estrogen.

The company said the drug is being evaluated in two ongoing phase 1 studies and will be evaluated in a phase 2 study in early 2018.